Clinical Trials, Phase II as Topic
"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017322
|
| MeSH Number(s) |
E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 4 | 4 |
| 2005 | 1 | 6 | 7 |
| 2006 | 1 | 4 | 5 |
| 2007 | 6 | 3 | 9 |
| 2008 | 2 | 0 | 2 |
| 2009 | 4 | 2 | 6 |
| 2010 | 3 | 2 | 5 |
| 2011 | 3 | 4 | 7 |
| 2012 | 5 | 4 | 9 |
| 2013 | 1 | 4 | 5 |
| 2014 | 3 | 9 | 12 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 5 | 5 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.
-
Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial). BMJ Open. 2023 04 06; 13(4):e068363.
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
-
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 Oct; 63(10):2413-2421.
-
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
-
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678.
-
The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022 02; 149(2):488-516.e9.
-
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
-
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021 Jun 01; 7(6):895-902.
-
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.